TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02737488

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Systems Therapy (TST)
Description: Treatment will be delivered by clinicians and trainees working at the CSC who have been trained in delivering TST. Participants who begin treatment in the safety-focused phase will have their treatment sessions in their homes. Whenever a child enters a different phase of treatment, he or she will go to the site for office visits. At the beginning of treatment, TST clinicians will do a brief diagnostic assessment. All documentation that is completed by the clinician as part of TST treatment at the NYU Langone Medical Center will be documented using Epic, a standard of care integrated health information system for patient safety. Although we are not providing the CSC's standard of care in this study,we are replicating standard care as TST is standard care in other settings. Providing medication is part of standard TST treatment and conforms to good usual practice integrated with psychotherapy. Medication will not be prescribed for research purposes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Youth in the control group will be referred to a mental health clinic in close proximity to their residence, in order to receive an evaluation and trauma treatment as usually provided. It cannot be specifically determined, in advance, the nature of this treatment.~The clinics will be contacted after the family enrolls to determine if there was a specific protocol followed. An NYU CSC research coordinator will contact the clinic and assist in scheduling the subject's first visit. Families who do not enroll in any community treatment or dropout of treatment will be followed according to the research protocol for data collection. At the 3, 6, and 9 month assessments, the research coordinator will request the patient's records from the community treatment clinic they are attending in order to track and keep record of the youth's treatment modality, progress, and visit frequency.
Study: NCT01762644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Cyclosporine and Oral Omeprazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Omeprazole
Study: NCT01994408

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: default intensification
Description: The investigators will determine which blood pressure medications to use. No specific drug will be tested but rather the automatic intensification of medications is the intervention. Examples of drugs used in this study are calcium channel blockers (e.g., amlodipine 2.5 mg to 10 mg) or ACE-inhibitors (e.g., lisinopril 5 mg to 40 mg) or diuretics (HCTZ 25 mg).
Study: NCT00473317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sun Exposure
Description: Each subject will wear a swimming suit and be exposed to sunlight for 30 minutes total (15 minutes lying on back, 15 minutes lying on stomach).
Study: NCT00760916

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UT-15C 1 mg
Description: UT-15C 1 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UT-15C 0.25 mg
Description: UT-15C 0.25 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UT-15C 5 mg
Description: UT-15C 5 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04311333

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Endostomal three-dimensional ultrasonography
Description: Examination with rectal probe enclosed by water-filled balloon. Rectal mode. Dynamic examination in different positions with and without increased intra-abdominal pressure.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computerized tomography of the abdomen
Description: Supine position, without increased intra-abdominal pressure. Experienced radiologist interprets the examination.~If adequate examination has already been performed within the last 10 months, these images will be used and the patient will thus not undergo computerized tomography within the study.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Clinical examination
Description: Patients will be clinically examined with inspection and palpation in supine and erect position with and without increased intra-abdominal pressure.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Evaluation at laparotomy/laparoscopy
Description: During laparotomy or laparoscopy, inspection and/or palpation of the stoma at the abdominal wall orifice is performed.
Study: NCT05696990

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3/7 Resistance Training Method
Description: 3/7 Resistance Training Method

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3X9 Resistance Training Method
Description: 3X9 Resistance Training Method
Study: NCT03992963

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing Aid without frequency lowering enabled
Description: Each participant will be fitted with frequency lowering disabled. Disabled means standard hearing loss compensation without lowering higher frequencies in lower frequency areas. The input frequency is mapped to the same frequency in output.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid with frequency lowering enabled
Description: Each participant will be fitted with frequency lowering enabled. The principle of the frequency lowering algorithm is to lower high frequencies to a lower frequency region with the aim of ensuring high frequency audibility to improve auditory emotion recognition.
Study: NCT04132323

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sclerotherapy
Description: Examination, photographing, inclusion in the study, signing of informed consent, randomization, diameter measurement, sclerotherapy according to the randomization group

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sclerotherapy
Description: Examination, photographing, inclusion in the study, signing of informed consent, randomization, diameter measurement, sclerotherapy according to the randomization group

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sclerotherapy
Description: Examination, photographing, inclusion in the study, signing of informed consent, randomization, diameter measurement, sclerotherapy according to the randomization group

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sclerotherapy
Description: Examination, photographing, inclusion in the study, signing of informed consent, randomization, diameter measurement, sclerotherapy according to the randomization group
Study: NCT00770783

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thymatron
Description: Right unilateral placement, 3x seizure threshold, 3 times per week for 4 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tonica MagPro MST
Description: 100% power, vertex placement, 3 times per week for 4 weeks
Study: NCT00841386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riboflavin-5-phosphate
Description: Riboflavin 0.1% (10 mg riboflavin-5-phosphate in 10 ml dextran T-500 20% solution, supplied in a sterile, single dose container) will be applied to the cornea every 2-3 minutes for 15 minutes prior to starting UV irradiation. The UV irradiation will be given in six 5 minute intervals. Additional riboflavin will be administered following each 5 minute UV treatment.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham cross-linking
Description: Topical anesthesia (lidocaine jelly 2%) will be used. Differing from the treatment group, no epithelium will be debrided, but instead, this step will be skipped and 2% methylcellulose solution with 1% sodium fluorescein will be applied to the cornea every 5 minutes for 15 minutes, and then every 5 minutes during the sham UV treatment. The patient will be placed under the UV device, and the aiming beam applied.
Study: NCT04725162

Intervention type: RADIATION
Intervention: 18F-FDG
Description: All subjects received 18F-FDG PET examination.

Intervention type: RADIATION
Intervention: 18F-FDG
Description: All subjects received 18F-FDG PET examination.
Study: NCT00276016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo capsules
Study: NCT04725162

Intervention type: RADIATION
Intervention: 18F-FDG
Description: All subjects received 18F-FDG PET examination.
Study: NCT04116840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT1002 for injection
Description: Study drug will be administered by an intravenous bolus dose followed by an infusion of 4 hours.
Study: NCT02386267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-leucine
Description: L-leucine pills per os for 6 months
Study: NCT00636519

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulism Antitoxin Bivalent (Equine) Types A and B
Description: One vial of Botulism Antitoxin Bivalent(Equine) Types A and B (1:10 in saline) or an Equivalent Volume of Placebo on Day 0 in Stage A

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulism Antitoxin Heptavalent (Equine) Types A-G
Description: One vial of Heptavalent Botulism Antitoxin (1:10 in saline) or an Equivalent Volume of Placebo on Day 0 in Stage B
Study: NCT04501237

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bruxers with sleep hygiene instructions
Description: the test group will receive instructions of sleep hygiene, limited use of screens and a relaxation audio.
Study: NCT01657721

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogmed Working Memory Training Program
Description: The Cogmed Working Memory Training Program will be used as the experimental program because of preliminary evidence indicating its effectiveness in enhancing WM and reducing behavioural symptoms of inattention/hyperactivity in children. This software-based training program was designed to improve WM abilities, particularly in children with ADHD or severe attention problems. It includes a set of auditory verbal and visual-spatial WM tasks presented via computer. All tasks involve: maintenance of simultaneous mental representations of multiple stimuli, unique sequencing of stimulus order in each trial and progressive adaptation of difficulty level as a function of individual performance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogmed Working Memory Training Program
Description: The Cogmed Working Memory Training Program will be used as the experimental program because of preliminary evidence indicating its effectiveness in enhancing WM and reducing behavioural symptoms of inattention/hyperactivity in children. This software-based training program was designed to improve WM abilities, particularly in children with ADHD or severe attention problems. It includes a set of auditory verbal and visual-spatial WM tasks presented via computer. All tasks involve: maintenance of simultaneous mental representations of multiple stimuli, unique sequencing of stimulus order in each trial and progressive adaptation of difficulty level as a function of individual performance.
Study: NCT03743597

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SOCKNLEG
Description: Innovative multilayer leg compression stocking, compression strength CEN compression class II (European Compression Strength) with compression at the ankle of 23-32mmhg, product composition understocking (polyamide, cotton, spandex), overstocking (polyamide, spandex)~In each participant all examinations will be performed with both study stockings, one after the other

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SOCKNLEG
Description: Innovative multilayer leg compression stocking, compression strength CEN compression class II (European Compression Strength) with compression at the ankle of 23-32mmhg, product composition understocking (polyamide, cotton, spandex), overstocking (polyamide, spandex)~In each participant all examinations will be performed with both study stockings, one after the other

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sigvaris COTTON
Description: Standard single leg compression stocking, compression strength CEN compression class II (European Compression Strength) with compression at the ankle of 23-32mmhg, product composition one stocking (polyamide, spandex, cotton)~In each participant all examinations will be performed with both study stockings, one after the other

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sigvaris COTTON
Description: Standard single leg compression stocking, compression strength CEN compression class II (European Compression Strength) with compression at the ankle of 23-32mmhg, product composition one stocking (polyamide, spandex, cotton)~In each participant all examinations will be performed with both study stockings, one after the other
Study: NCT04091945

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LT3001 Drug Product
Description: Active comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT02228083

Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine with epinephrine
Description: Lidocaine without vasoconstrictor , lidocaine with epinephrine 1:100,000

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine with epinephrine
Description: Lidocaine without vasoconstrictor , lidocaine with epinephrine 1:100,000
Study: NCT03946319

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Introspect Health
Description: Introspect Health is a software platform which has implemented both the monotopic and personalized, transdiagnostic assessment tools. The software is delivered via the internet using a mobile device or computer.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Introspect Health
Description: Introspect Health is a software platform which has implemented both the monotopic and personalized, transdiagnostic assessment tools. The software is delivered via the internet using a mobile device or computer.
Study: NCT00866281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midostaurin
Description: Midostaurin 25 mg/mL oral solution was provided in bottles of 50 mL, administered with water. The pediatric starting dose of midostaurin was set at 30 mg/m2 bid and was not to exceed 60 mg/m2 bid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midostaurin
Description: Midostaurin 25 mg/mL oral solution was provided in bottles of 50 mL, administered with water. The pediatric starting dose of midostaurin was set at 30 mg/m2 bid and was not to exceed 60 mg/m2 bid.
Study: NCT03426618

Intervention type: OTHER
Intervention: Non-interventional
Description: Non-interventional
Study: NCT01588769

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALECSAT cell based immunotherapy
Description: I.V. injected Cell Based Medicinal Product, containing between 10 million and one billion autologous Cytotoxic T cells and Natural Killer cells.
Study: NCT03010384

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation program
Study: NCT04412109

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thoracic epidural catheterization
Description: thoracic epidural catheterization for postoperative pain control

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thoracic epidural catheterization
Description: thoracic epidural catheterization for postoperative pain control

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thoracic epidural catheterization
Description: thoracic epidural catheterization for postoperative pain control
Study: NCT02678793

Intervention type: DRUG
Group type: OTHER
Intervention: CNTX-4975
Study: NCT01630187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbetocin
Description: Administration of carbetocin 50 mcg , after clamping the umbilical cord

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Administration of carbetocin 100 mcg , after clamping the umbilical cord
Study: NCT04439474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: For up to 8 days, 50,000 units of vitamin D3 are given daily to patients in the first group so that the serum level of vitamin D reaches above 30 g / ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Routine treatment
Description: In this group, patients receive their usual medications and treatments
Study: NCT02746718

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: A blood sample for CPK dosage and pompe disease test
Study: NCT03039504

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potensa, a succinate-based dietary supplement
Description: Potensa - a dietary supplement: 4 capsules (2 white 200mg each and 2 blue 200 mg each) once a day with a meal or immediately after a meal, preferably after breakfast, for 3 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 4 capsules (2 white 200mg each and 2 blue 200 mg each) once a day with a meal or immediately after a meal, preferably after breakfast, for 3 months.
Study: NCT01833481

Intervention type: RADIATION
Intervention: Fluoroscopy surveillance of patients while walking
Description: While each subject performs a gait activity (normal walking) under fluoroscopic surveillance on a level treadmill, a data acquisition (DAQ) system will be used to determine the vibrations/sounds occurring during walking.

Intervention type: RADIATION
Intervention: Fluoroscopy surveillance of patients while walking
Description: While each subject performs a gait activity (normal walking) under fluoroscopic surveillance on a level treadmill, a data acquisition (DAQ) system will be used to determine the vibrations/sounds occurring during walking.

Intervention type: RADIATION
Intervention: Fluoroscopy surveillance of patients while walking
Description: While each subject performs a gait activity (normal walking) under fluoroscopic surveillance on a level treadmill, a data acquisition (DAQ) system will be used to determine the vibrations/sounds occurring during walking.
Study: NCT01731132

Intervention type: DRUG
Intervention: Levonorgestrel IUD or Copper IUD
Description: Women who initiate the use of an IUD at the time of the study.
Study: NCT03216122

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional/Delayed Loading

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Loading
Study: NCT04090060

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Practice Self-/Companion Exams
Description: 300 men and 50 couples will be randomized and encouraged to practice anal exams at home before Visit 2. Practice results will be elicited by staff. They will return for Visit 2 (six months after Visit 1). At Visit 2, they will complete a pre- and post-visit computer assisted self-interview. They will receive written instructions. After completing an anal self-exam or anal companion exam at home, they will record the results. At the clinic, they will have a Digital Anal Rectal Exam (DARE) by a clinician who will give the subject his results.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control Arm
Description: 300 individuals and 50 couples will be randomized to this arm. Following Visit 1, they will neither be encouraged nor discouraged from practicing self- or companion exam. They will return for Visit 2 (six months after Visit 1). They will receive written anal exam instructions. They will then complete the self- or companion exam at home, and record the results. At the clinic, they will receive a clinician DARE. Clinicians will give DARE results. Persons will take a post-exam computer-assisted self-interview. Persons in this arm (control) will be asked if they have performed exams between visits.
Study: NCT01447550

Intervention type: DRUG
Intervention: Bosentan
Description: Bosentan therapy consisted of a month's treatment with 62.5 mg bid orally administered. Dose doubled to 125 mg bid after the first month. The full-dose regimen (125 mg/12h) was maintained for the following months or until total healing fo the ulcers.
Study: NCT02619630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nelarabine
Description: Nelarabine 1500 mg/m2/d (IV 2h) : D1, D3, D5 Cyclophosphamide 150 mg/m2/d (IV 3h) : D1, D3 etoposide (VP-16) 75 mg/m2/d (IV 1h) : D1, D3 granulocyte-colony stimulating factor 5 µg/kg/d (SC) : D7 until neutrophil \>1 Giga/Liter~for a maximum of 5 blocks
Study: NCT02734537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01472042

Intervention type: OTHER
Intervention: Banyan Biomarkers
Description: Biomarkers to detect specific proteins.

Intervention type: OTHER
Intervention: Banyan Biomarkers
Description: Biomarkers to detect specific proteins.

Intervention type: OTHER
Intervention: Banyan Biomarkers
Description: Biomarkers to detect specific proteins.
Study: NCT01203514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: Infants received 400 U/kg Erythropoietin (Epo) 3 times weekly and a weekly intravenous infusion of 5 mg/kg iron dextran until they had an enteral intake of 60 mL/kg/d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: Infants received 400 U/kg Erythropoietin (Epo) 3 times weekly and a weekly intravenous infusion of 5 mg/kg iron dextran until they had an enteral intake of 60 mL/kg/d.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: Infants in the placebo/control group received sham subcutaneous injections when intravenous access was not available.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: Infants in the placebo/control group received sham subcutaneous injections when intravenous access was not available.
Study: NCT01001273

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic Normoglycemic Clamp
Description: The patient receives insulin intravenous infusion at 2ml units/kg/min. Dextrose 20% (D20W ®) will be titrated to maintain blood glucose between 4 - 6 mmol/L (72 - 108 mg/dl).
Study: NCT00961350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA32540
Description: PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EC Aspirin 325
Description: The comparator aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole)
Study: NCT00571727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mecasermin
Description: injections BID of rhIGF-1, mecasermin